Navigation Links
Astellas Pharma Inc.: New Hire Reinforces Global Compliance Structure
Date:4/14/2013

TOKYO, April 14, 2013 /PRNewswire/ -- Astellas Pharma Inc. ("Astellas"; Tokyo: 4503) today announced that Songlin Xue , M.D., Ph.D. has been named head of Global Pharmacovigilance (GPV). Dr. Xue will be located at Astellas' Headquarters for the Americas in Northbrook, Illinois, USA and will report to Sef Kurstjens , M.D., Ph.D., newly named Chief Medical Officer at Astellas. In April 2013, Astellas established the Chief Medical Officer position in order to further integrate and enhance Astellas' delivery of global medical solutions.

Astellas President and CEO Yoshihiko Hatanaka said, "I am pleased that Dr. Xue will be joining us at Astellas as head of Global Pharmacovigilance. Dr. Xue's knowledge and experience will help the company pursue its operational excellence and further enhance our global PV and product compliance capabilities."

With Dr. Xue's appointment, Astellas has now completed the hiring of global heads in the areas of PV, Medical Affairs, Regulatory Affairs, Clinical and Research Quality Assurance, and Quality Assurance.

During his more than twenty years in the pharmaceutical industry, Dr. Xue has held increasingly senior roles with global responsibilities in drug safety and pharmacoepidemiology.  Most recently, Dr. Xue held the position of Senior Vice President, Head Global Pharmacovigilance at Takeda Pharmaceuticals, Inc. Prior to joining Takeda, Dr. Xue held posts with global pharmaceutical companies such as Novartis and Wyeth. 

Dr. Xue received his medical degree from Shanxi Medical College in Shanxi China.  Subsequently, he received a Masters of Science (clinical epidemiology) degree from Hunan University of Medical Science, Hunan, China, and a Doctor of Philosophy degree (Ph.D.) in epidemiology from the University of Minnesota. 

About Astellas Pharma Inc.
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 17,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology (including Transplantation) and Infectious Diseases, Oncology, Neuroscience and DM Complications and Kidney Diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.  


'/>"/>
SOURCE Astellas Pharma Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
2. Astellas and Fujita Health University Discover Neuronal Maturation Deficits in Patients Suffering from Schizophrenia and Bipolar Disorder
3. Astellas to Close Urogenix, North Carolina-based Urology Research Facility
4. Personal Connections Drive Employee Participation For Changing Tomorrow Day at Astellas
5. Astellas Announces Acceptance of U.S. New Drug Application for Tacrolimus Extended Release Capsules
6. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
7. Astellas Highlights Progress to Advance Care of Patients with Genitourinary Cancers at ASCO-GU Annual Meeting
8. Astellas to Drive PGA TOURs New Womens Initiative
9. PGA TOUR Celebrates Official Launch of the Astellas Presents Executive Womens Day Program
10. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... 2016 Roche (SIX: RO, ROG; OTCQX: RHHBY) ... Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated testing ... With this clearance, Roche is the first IVD company ... for sepsis risk assessment and management. PCT ... PCT levels in blood can aid clinicians in assessing ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... patient payment industry today announced its strategic partnership with Connance, a healthcare ... , The two companies’ proven, proprietary technology combine to provide health systems, ...
(Date:6/26/2016)... ... 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic ... World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. ... some of the world’s leading providers of cereal and other breakfast foods. Its residents ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, ... Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms ... Final Cut Pro X . Simply select a ProHand generator and drag it above ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
Breaking Medicine News(10 mins):